|Mr. Scott Raymond Ward M.S., MS, B.Sc.||Chairman, Pres & CEO||1.17M||N/A||1960|
|Mr. Jeffrey S. Points||Chief Financial Officer||507.49k||N/A||1977|
|Ms. Rhonda J. Robb||Chief Operating Officer||830.22k||N/A||1968|
|Mr. Alexander Rosenstein||Gen. Counsel & Corp. Sec.||523.26k||N/A||1972|
|Dr. Ryan D. Egeland M.D., Ph.D.||Chief Medical Officer||490.64k||N/A||1975|
|Mr. John E. Nielsen||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Ms. Sandra M. Sedo||Chief Compliance Officer||N/A||N/A||1964|
|Mr. David S. Whitescarver||VP of Corp. Devel. & Intellectual Property||N/A||N/A||1958|
|Mr. Stephen J. Rempe||Chief HR Officer||N/A||N/A||1973|
Cardiovascular Systems, Inc., a medical device company, develops and commercializes various devices to treat peripheral and coronary artery diseases in the United States. The company offers peripheral artery disease products, which are catheter-based platforms to treat a range of plaque types in above and below the knee leg arteries, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. The company has a partnership with Chansu Vascular Technologies, LLC to develop novel peripheral and coronary everolimus drug-coated balloons. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in St. Paul, Minnesota.
Cardiovascular Systems, Inc.’s ISS governance QualityScore as of 2 December 2020 is 3. The pillar scores are Audit: 2; Board: 2; Shareholder rights: 6; Compensation: 1.